SCINAI IMMUNOTHERAPEUTICS LTD
General Data
Reg Number
513436105
Sector
Biomed
Established
2003
No. of Employees
40
Stage
Initial Revenues
Additional Funding
1
Description
Scinai BioServices supports biopharma innovators from early research to late-phase clinical production, delivering agile, cost-effective, and science-driven CDMO solutions backed by over 20 years of experience and a state-of-the-art cGMP facility
Technology
Alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies, exhibit potential as biobetter therapies for a wide range of diseases. Scinai is developing NanoAbs addressing diseases with large unmet medical needs and attractive commercial opportunities, such as psoriasis and asthma.
Targeted Customers
Leading pharmaceuticals, governments and global health organizations, biotechnology and vaccine companies.
Management personnel
Winning details
Route name
Winning year
Infrastructure and Equipment for R&D
Infrastructure and Equipment for R&D
2023
Increasing participation of Israeli industrial corporations in the European Horizon program
Increasing participation of Israeli industrial corporations in the European Horizon program
2023
Establishment of R&D labs and databases accessible to the entire industry – R&D Infrastructures Fund
Establishment of R&D labs and databases accessible to the entire industry – R&D Infrastructures Fund
2025